Roche Holding (RHHBY) AI Stock Analysis

Roche Holding

(Other OTC:RHHBY)

Select Model

Rating:71Outperform

Price Target:$66.00▲(9.36% Upside)

Action:reiterated

Date:10/23/26

The score is driven primarily by strong underlying financial quality (high margins and solid cash generation) and a constructive earnings call with reaffirmed guidance, margin expansion, and strong pipeline/regulatory momentum. Offsetting these positives are uneven historical growth, meaningful leverage, overbought technical signals that increase near-term pullback risk, and a valuation that looks elevated at ~25.5x earnings despite a moderate ~2.6% dividend yield.

Positive Factors

High profitability and cash generationRoche combines high gross and operating margins with consistently positive free cash flow, indicating a strong economic model and meaningful internal funding capacity. This supports continued investment in research, launches and commercial infrastructure while providing resilience across the next several quarters.

Negative Factors

Meaningful leverageAlthough leverage improved, Roche’s financing mix still provides less balance-sheet cushion than more conservatively funded peers. Higher debt relative to equity can constrain flexibility for acquisitions, shareholder distributions and research investment if earnings or cash generation weaken.

Roche Holding (RHHBY) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $390.66B
Dividend Yield: 2.53%
Average Volume (3M): 1.78M
Price to Earnings (P/E): 26.3
Beta (1Y): 0.36
Revenue Growth: 8.13%
EPS Growth: 42.71%
Country: US
Employees: 103,249
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - General

Roche Holding Business Overview & Revenue Model

Company Description

Roche Holding AG functions as a major global healthcare enterprise, primarily concentrating its efforts within the pharmaceutical and diagnostic sectors. The company boasts an extensive international presence, with key operations located in countries...

How the Company Makes Money

Roche makes money primarily by selling healthcare products through its Pharmaceuticals and Diagnostics divisions. In Pharmaceuticals, revenue is generated from the sale of patented prescription medicines to wholesalers, hospitals, pharmacies, and hea...

Roche Holding Earnings Call Summary

Earnings Call Date:Jul 22, 2026(Q2-2026)|% Change Since:16.73%|Next Earnings Date:Jan 27, 2027

Earnings Call SentimentPositive

Overall the call conveyed a positive operating and pipeline momentum despite identifiable headwinds. Roche reported strong profitability (core op profit +10%, margin expansion), solid organic growth in Pharma, multiple regulatory wins (5 priority reviews) and major diagnostics and R&D milestones (AXELIOS launch, CE marks, strategic M&A). Offsetting items include China pricing reform and a weak respiratory season hitting Diagnostics, currency translation pressures, a near‑term net debt increase (timing effects) and some competitive/biosimilar pressure in specific franchises. On balance, the operational and pipeline achievements materially outweigh the manageable challenges described.

Positive Updates

Strong profitability and margin expansion

Core operating profit up 10% (constant exchange rates) with core operating margin +1.7 percentage points; core EPS +9% (CER). Operating free cash flow +21% and free cash flow +58% (timing effects), demonstrating strong cash generation and margin discipline.

Negative Updates

China pricing reform significantly weighing on Diagnostics

China sales in Diagnostics declined ~15% (APAC -5% overall), with health‑care pricing reform materially reducing reported Diagnostics growth; excluding China effect Diagnostics would have grown +6%.

Company Guidance

Roche confirmed its 2026 guidance: mid‑single‑digit group sales growth (sales are running ~6% YTD) and high‑single‑digit core EPS growth (core EPS up ~9% H1), while reporting core operating profit up 10% YTD and a 1.7 percentage‑point improvement in core operating margin; management reiterated an expected LOE impact of ~CHF 600m for 2026, aims to keep Diagnostics’ margin broadly stable versus 2025 (14.4% CER) with Diagnostics growth targeted at mid‑single‑digits in 2026 (and mid‑ to high‑single‑digits in 2027), expects the core tax rate to normalize toward ~20% for the full year, flagged currency headwinds of roughly -4 p.p. on sales and -6 p.p. on core operating profit/core EPS for the year, said other revenue should rise from ~3% to ~5% of sales by the end of the decade, and confirmed a further increase in the dividend in Swiss francs.

Roche Holding Financial Statement Overview

Summary

Strong profitability and margins (gross margin ~69%–74%, EBIT margin ~21%–32%) with a notable earnings rebound in 2025. Cash generation is consistently positive with improving FCF in 2024–2025, but cash conversion (OCF vs. EBIT) has been weaker and growth has been uneven across years. Balance sheet is solid but leverage remains meaningful (debt-to-equity often ~1.0+, improving to ~0.94 in 2025), reducing flexibility if earnings soften.

Income Statement

78Positive

Balance Sheet

67Positive

Cash Flow

71Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	61.34B	63.36B	62.40B	60.44B	65.81B	62.80B
Gross Profit	44.62B	46.71B	46.11B	44.84B	47.88B	43.10B
EBITDA	23.89B	21.70B	16.62B	18.40B	24.41B	22.19B
Net Income	12.44B	12.88B	8.28B	11.50B	12.42B	13.93B
Balance Sheet
Total Assets	97.85B	100.82B	101.80B	90.47B	88.15B	92.32B
Cash, Cash Equivalents and Short-Term Investments	9.70B	15.49B	17.32B	10.51B	9.77B	13.03B
Total Debt	31.69B	33.19B	36.35B	30.78B	26.54B	32.55B
Total Liabilities	61.27B	62.89B	65.64B	57.20B	56.14B	63.97B
Stockholders Equity	32.58B	33.84B	31.77B	29.32B	27.99B	24.49B
Cash Flow
Free Cash Flow	15.16B	13.45B	15.09B	11.45B	13.34B	16.02B
Operating Cash Flow	18.94B	17.03B	20.09B	16.09B	17.89B	20.57B
Investing Cash Flow	-7.85B	-8.32B	-11.39B	-10.64B	-3.57B	-6.55B
Financing Cash Flow	-13.01B	-9.72B	-6.82B	-4.24B	-15.72B	-12.70B

Roche Holding Technical Analysis

Technical Analysis SentimentPositive

Last Price60.35

Price Trends

50DMA55.61Positive

100DMA54.38Positive

200DMA53.49Positive

Market Momentum

MACD1.80Negative

RSI72.30Negative

STOCH82.63Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RHHBY, the sentiment is Positive. The current price of 60.35 is above the 20-day moving average (MA) of 57.14, above the 50-day MA of 55.61, and above the 200-day MA of 53.49, indicating a bullish trend. The MACD of 1.80 indicates Negative momentum. The RSI at 72.30 is Negative, neither overbought nor oversold. The STOCH value of 82.63 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RHHBY.

Roche Holding Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

RHHBY against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PFE	74Outperform	$173.95B	40.33	4.89%	5.64%	-0.21%	-59.71%
ABBV	72Outperform	$521.11B	50.58	-223.75%	2.35%	10.68%	―
NVS	72Outperform	$296.91B	31.19	24.24%	2.95%	1.64%	-28.72%
RHHBY	71Outperform	$390.13B	26.26	37.12%	2.53%	8.13%	42.71%
JNJ	70Outperform	$657.68B	41.42	19.55%	1.93%	7.81%	-35.95%
MRK	63Neutral	$368.89B	152.57	5.10%	2.27%	5.16%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

RHHBY and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
RHHBY	Roche Holding AG	61.27	21.89	55.60%
JNJ	Johnson & Johnson	273.20	91.04	49.98%
MRK	Merck & Company	149.52	69.38	86.58%
NVS	Novartis AG	160.79	39.31	32.36%
PFE	Pfizer Inc	30.52	7.48	32.45%
ABBV	Abbvie	294.89	89.09	43.29%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 23, 2026

Roche Holding AI Stock Analysis